Literature DB >> 25473000

Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.

James H Park1, Donald C McMillan2, Arfon G Powell3, Colin H Richards2, Paul G Horgan2, Joanne Edwards4, Campbell S D Roxburgh2.   

Abstract

PURPOSE: The tumor microenvironment is recognized as an important determinant of progression and outcome in colorectal cancer. The aim of the present study was to evaluate a novel tumor microenvironment-based prognostic score, based on histopathologic assessment of the tumor inflammatory cell infiltrate and tumor stroma, in patients with primary operable colorectal cancer. EXPERIMENTAL
DESIGN: Using routine pathologic sections, the tumor inflammatory cell infiltrate and stroma were assessed using Klintrup-Mäkinen (KM) grade and tumor stroma percentage (TSP), respectively, in 307 patients who had undergone elective resection for stage I-III colorectal cancer. The clinical utility of a cumulative score based on these characteristics was examined.
RESULTS: On univariate analysis, both weak KM grade and high TSP were associated with reduced survival (HR, 2.42; P = 0.001 and HR, 2.05; P = 0.001, respectively). A cumulative score based on these characteristics, the Glasgow Microenvironment Score (GMS), was associated with survival (HR, 1.93; 95% confidence interval, 1.36-2.73; P < 0.001), independent of TNM stage and venous invasion (both P < 0.05). GMS stratified patients in to three prognostic groups: strong KM (GMS = 0), weak KM/low TSP (GMS = 1), and weak KM/high TSP (GMS = 2), with 5-year survival of 89%, 75%, and 51%, respectively (P < 0.001). Furthermore, GMS in combination with node involvement, venous invasion, and mismatch repair status further stratified 5-year survival (92% to 37%, 93% to 27%, and 100% to 37%, respectively).
CONCLUSIONS: The present study further confirms the clinical utility of assessment of the tumor microenvironment in colorectal cancer and introduces a simple, routinely available prognostic score for the risk stratification of patients with primary operable colorectal cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25473000     DOI: 10.1158/1078-0432.CCR-14-1686

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.

Authors:  Zhi-Hua Zhou; Cheng-Dong Ji; Jiang Zhu; Hua-Liang Xiao; Hai-Bin Zhao; You-Hong Cui; Xiu-Wu Bian
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-08       Impact factor: 4.553

2.  MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.

Authors:  Kosuke Mima; Reiko Nishihara; Juhong Yang; Ruoxu Dou; Yohei Masugi; Yan Shi; Annacarolina da Silva; Yin Cao; Mingyang Song; Jonathan Nowak; Mancang Gu; Wanwan Li; Teppei Morikawa; Xuehong Zhang; Kana Wu; Hideo Baba; Edward L Giovannucci; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

3.  Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.

Authors:  Katarzyna Jakubowska; Wojciech Kisielewski; Luiza Kańczuga-Koda; Mariusz Koda; Waldemar Famulski
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

4.  The relationship between members of the canonical NF-kB pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients.

Authors:  Jean A Quinn; Lindsay Bennett; Meera Patel; Mikaela Frixou; James H Park; Antonia Roseweir; Paul G Horgan; Donald C McMillan; Joanne Edwards
Journal:  Histol Histopathol       Date:  2019-10-08       Impact factor: 2.303

5.  Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer.

Authors:  J H Park; D C McMillan; J Edwards; P G Horgan; C S D Roxburgh
Journal:  Oncoimmunology       Date:  2016-03-21       Impact factor: 8.110

Review 6.  Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions.

Authors:  Jennifer Alexander; Edna Cukierman
Journal:  Curr Opin Cell Biol       Date:  2016-05-20       Impact factor: 8.382

7.  MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression.

Authors:  John R P Knight; Constantinos Alexandrou; George L Skalka; Nikola Vlahov; Kathryn Pennel; Leah Officer; Ana Teodosio; Georgios Kanellos; David M Gay; Sebastian May-Wilson; Ewan M Smith; Arafath K Najumudeen; Kathryn Gilroy; Rachel A Ridgway; Dustin J Flanagan; Rachael C L Smith; Laura McDonald; Craig MacKay; Anne Cheasty; Kerri McArthur; Emma Stanway; Joshua D Leach; Rene Jackstadt; Joseph A Waldron; Andrew D Campbell; Georgios Vlachogiannis; Nicola Valeri; Kevin M Haigis; Nahum Sonenberg; Christopher G Proud; Neil P Jones; Martin E Swarbrick; Heather J McKinnon; William J Faller; John Le Quesne; Joanne Edwards; Anne E Willis; Martin Bushell; Owen J Sansom
Journal:  Cancer Discov       Date:  2020-12-16       Impact factor: 38.272

8.  The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  Hester C van Wyk; James H Park; Joanne Edwards; Paul G Horgan; Donald C McMillan; James J Going
Journal:  Br J Cancer       Date:  2016-06-14       Impact factor: 7.640

9.  Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.

Authors:  Rachael Natrajan; Heba Sailem; Faraz K Mardakheh; Mar Arias Garcia; Christopher J Tape; Mitch Dowsett; Chris Bakal; Yinyin Yuan
Journal:  PLoS Med       Date:  2016-02-16       Impact factor: 11.069

Review 10.  Fibrosis imaging: Current concepts and future directions.

Authors:  Maike Baues; Anshuman Dasgupta; Josef Ehling; Jai Prakash; Peter Boor; Frank Tacke; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2017-11-20       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.